Company intelligence / Profile preview

Quintessence Biosciences, Inc.

Madison, Wisconsin, United Statesventureradar.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Quintessence Biosciences developed protein-based anti-cancer drugs using its proprietary EVade™ Ribonuclease technology. Its lead candidate QBI‑139 entered Phase I clinical trials for solid tumors around late 2008–2009. Preclinical studies showed significant tumor growth inhibition across several cancers with minimal toxicity. The company also worked on next-generation candidates such as PEGylated variants to improve efficacy and pharmacokinetics. No later-stage or commercial results are reported due to the company's closure by ~2017.

Therapeutic areas: Oncology
Modalities: Protein therapeutics (engineered ribonucleases)Recombinant proteinsPEGylated proteins
Industry: Biotech

Drug pipeline

1 asset

QBI-139

Beyond the preview

Go deeper on Quintessence Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Quintessence Biosciences, Inc..

Explore the full profile